Page last updated: 2024-12-08

metrizamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443944
CHEMBL ID462394
CHEBI ID31841
SCHEMBL ID24382
SCHEMBL ID16984723
MeSH IDM0013690

Synonyms (38)

Synonym
MLS002153823
smr001233191
2-[({3-(acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodophenyl}carbonyl)amino]-2-deoxy-d-glucopyranose
metrizamide
BSPBIO_000566
NCGC00179520-01
BPBIO1_000624
PRESTWICK3_000463
AB00513843
D01311
amipaque (tn)
metrizamide (jan/usan/inn)
CHEMBL462394
3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-n-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
HMS2096M08
tox21_110619
dtxsid1023310 ,
HMS2230M07
AKOS015965061
CCG-220463
SCHEMBL24382
55134-11-7
3-acetamido-2,4,6-triiodo-5-(n-methylacetamido)-n-((3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)benzamide
AB00513843_06
3-acetamido-2,4,6-triiodo-5-(n-methylacetamido)-n-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
SCHEMBL16984723
CS-W000133
SR-01000841219-2
sr-01000841219
J-018245
CHEBI:31841
HMS3713M08
Q6824399
STL564457
NCGC00179520-04
D77558
MS-31452
HY-W000133

Research Excerpts

Overview

Metrizamide is a water-soluble glucose amide containing three iodine molecules. Metrizamide seems to be a suitable contrast medium for ventriculography and myelography.

ExcerptReferenceRelevance
"Metrizamide is a water-soluble contrast medium used as a diagnostic tool in myelography and cisternography. "( Generalized motor seizure following metrizamide cisternography.
Adelman, DC; Ellis, JC; Saltiel, E; Young, WI, 1984
)
1.99
"Metrizamide appears to be a relatively safe and effective agent for examination of the neonatal gastrointestinal tract."( Effect of oral metrizamide on hematocrit and serum osmolality in the neonate.
Clarke, E; Siegle, RL,
)
1.21
"Metrizamide is a nondissociable, water-soluble glucose amide containing three iodine molecules."( Metrizamide cisternography in the investigation of the empty sella syndrome.
Falko, JM; Zull, DN, 1981
)
2.43
"Metrizamide is a water-soluble isotonic contrast material having many advantages over barium and existing hypertonic water-soluble agents."( The use of metrizamide (amipaque) to visualise the gastrointestinal tract in children: a preliminary report.
Cohen, M; Gresham, EL; Lemons, J; Schreiner, R; Smith, JA; Smith, WL, 1980
)
1.37
"Metrizamide seems to be a suitable contrast medium for ventriculography and myelography. "( Metrizamide in radiography of the central nervous system. A preliminary report.
Hauglie-Hanssen, E; Lundervold, A; Sortland, O; Svare, A, 1976
)
3.14
"Metrizamide is a nonionic water-soluble contrast medium for neuroradiological studies that is less irritating to the nervous system than other water-soluble agents. "( Clinical evaluation of metrizamide for neuroradiology in chilren.
Haughton, VM; Sty, JR; Swick, HM, 1978
)
2.01
"Metrizamide (Amipaque) is a new water-soluble contrast agent for use in the intrathecal space. "( Application of metrizamide in the radiographic evaluation of the neurologically diseased patient.
Diehl, JT; Maravilla, KR; Neuwelt, EA, 1979
)
2.06
"Metrizamide (Amipaque) is a new water-soluble contrast medium for myelography. "( Myelography with metrizamide.
Peeters, FL, 1977
)
2.04
"Metrizamide is a water-soluble, nonionic radiocontrast medium that penetrates better into narrow subarachnoid spaces than do oily contrast media or gas. "( Cat optic nerve imaging with metrizamide.
Davis, JP; Eldevik, OP; Gager, WE; Harris, GJ; Haughton, VM, 1979
)
1.99
"Metrizamide (Amipaque) is a new, non-dissociating contrast medium enabling completely painless angiographic examination of the arteries of the lower extremities. "( [Angiography of the femoral artery with metrizamide without narcosis (author's transl)].
Holsten, DR; Wille, C, 1979
)
1.97
"Metrizamide is a non-ionised, water soluble, and completely absorbable contrast medium which can be used to demonstrate all sections of the spinal canal. "( [Myelography with metrizamide (author's transl)].
Graser, C; Kohlmeyer, K; Papke, M, 1979
)
2.04
"Metrizamide is a new hydrosoluble contrast medium of an entirely original conception which for first time makes it possible to explore the whole cord and its spaces. "( [Cervical myelography using metrizamide via a lateral approach at C1-C2 (author's transl)].
Bonafe, A; Manelfe, C; Treil, J, 1978
)
2
"Metrizamide is an attractive myelographic agent with several advantages over other available myelographic agents. "( Comparison of metrizamide with other myelographic agents.
Bentson, JR, 1977
)
2.06
"Metrizamide is a non-ionic water-soluble contrast medium which is isotonic with human blood and tissue fluid at a concentration of 170 mgI/ml. "( Orbitography with a new non-ionizing water-soluble contrast medium.
Arnesen, K; Evensen, A; Johansen, JG; Udnaes, I, 1976
)
1.7
"Metrizamide is a new non-ionic water soluble contrast agent. "( Addition of calcium or other cations and of oxygen to ionic and non-ionic contrast media. Effects on cardiac function during coronary arteriography.
Almén, T; Lynch, P; Trägårdh, B,
)
1.57
"Metrizamide is a safe, water-soluble contrast medium suitable for bedside gastrointestinal studies in low-birth-weight infants. "( Use of low osmolar contrast for gastrointestinal studies in low-birth-weight infants.
Dutton, RV; Singleton, EB, 1987
)
1.72
"Metrizamide is a widely used contrast medium with some well known adverse reactions. "( The penetration of metrizamide into the brain after routine lumbar myelography as shown by cerebral computed tomography and its effect on auditory brainstem transmission time.
Björnsson, A; Brekkan, A; Hannesson, B; Sigurjónsson, K; Snorrason, E; Valdimarsson, E, 1985
)
2.04

Effects

Metrizamide (Amipaque) has been used to image the bowel of four neonates and one older child with possible bowel obstruction. Metrizamide has replaced Pantopaque and gas as the most commonly used intrathecal contrast agent at the University of Texas Health Science Center at Dallas.

ExcerptReferenceRelevance
"Metrizamide probably has a lower neurotoxicity than any other known water-soluble contrast agent."( Lumbar myelography with metrizamide-a new non-ionic contrast medium.
Grainger, RG, 1976
)
1.28
"Metrizamide has been found to be a superior agent for this purpose, permitting visualization of the cord shadow in the anteroposterior as well as the lateral projection, and thereby also enabling the surgeon to visualize displacement of the spinal cord during the procedure."( Use of metrizamide for percutaneous cordotomy. Technical note.
Batzdorf, U; Bentson, JR, 1983
)
1.44
"Metrizamide (Amipaque) has been used to image the bowel of four neonates and one older child with possible bowel obstruction. "( Metrizamide in neonatal and childhood small bowel obstruction.
Cohen, MD; Weber, T, 1982
)
3.15
"Metrizamide (amipaque) has not been used previously as a diagnostic contrast agent in the gastrointestinal tract. "( The use of metrizamide (amipaque) to visualise the gastrointestinal tract in children: a preliminary report.
Cohen, M; Gresham, EL; Lemons, J; Schreiner, R; Smith, JA; Smith, WL, 1980
)
2.09
"Metrizamide (Amipaque) has been used as the contrast medium for angiography in neuroradiological investigations. "( [Cerebral and spinal angiography with metrizamide (amipaque) (author's transl)].
Schmidt, RC; Stöppler, L; Vogelsang, H, 1978
)
1.97
"Metrizamide (Amipaque) has been used to evaluate 20 patients with Chiari malformations, achondroplasia, and conditions related to scoliosis."( Myelography with metrizamide in intraspinal and spinal abnormalities.
Breed, AL; Hausserman, SA; Okagaki, HI; Sackett, JF, 1977
)
1.32
"Metrizamide has now replaced Pantopaque and gas as the most commonly used intrathecal contrast agent at the University of Texas Health Science Center at Dallas."( Application of metrizamide in the radiographic evaluation of the neurologically diseased patient.
Diehl, JT; Maravilla, KR; Neuwelt, EA, 1979
)
1.33
"Metrizamide probably has a lower neurotoxicity than any other known water-soluble contrast agent."( Lumbar myelography with metrizamide-a new non-ionic contrast medium.
Grainger, RG, 1976
)
1.28
"Metrizamide has been described as a new medium for isopycnic centrifugation of unfixed biological particles. "( [Isopycnic centrifugation in metrizanide gradient of ribosomal ribonucleoprotein precursor particles].
Auger, MA; Longuet, M, 1976
)
1.7
"Metrizamide has been used for examination of the gastrointestinal tract and tracheobronchial tree of infants. "( Lung tumor incidence after intrabronchial administration of the nonionic contrast agent metrizamide.
Alford, BA; Baker, DG; Feldman, PS, 1992
)
1.95
"Metrizamide has been well known to cause convulsive seizures even in patients without epilepsy."( Absence status epilepticus resulting from metrizamide and omnipaque myelography.
Ahmed, I; Jones, RP; Pepple, R, 1988
)
1.26
"Metrizamide neurotoxicity has been hypothesized to be caused by an inhibitory effect of the drug on glucose metabolism. "( Further support for the glucose hypothesis of metrizamide toxicity. The effect of metrizamide and glucose analogue-free contrast media on hexokinase.
Ekholm, SE; Fonte, DJ; Morris, TW; Simon, JH, 1987
)
1.97

Actions

ExcerptReferenceRelevance
"Metrizamide may cause pathologic changes that must be recognized for the correct interpretation by the pathologist of tissue sections previously exposed to metrizamide."( The histologic effect of intraventricular injection of metrizamide.
Auer, RN; Fox, AJ; Kaufmann, JC, 1982
)
1.23

Treatment

ExcerptReferenceRelevance
"Treatment with metrizamide appeared to be a less deleterious procedure than that using hyperosmotic sucrose (1.32 M) as judged from EMG records."( Intrathecal tolerance of metrizamide in chloralose anesthetized cats.
Healey, JF; Piwonka, RW; Rosenberg, FJ,
)
0.77

Toxicity

Metrizamide provides a finer myelographic assessment of the spinal neuroanatomical structures. Following metrizamide myelography, patients can be encouraged to be ambulatory without any increase in the incidence of adverse effects.

ExcerptReferenceRelevance
" Amipaque had a significantly higher LD50 than Isopaque Coronar (17."( Studies on the acute toxicity of ionic and non-ionic contrast media following rapid intravenous injection. An experimental study in mice.
Almén, T; Aspelin, P,
)
0.13
"Radiographic quality as well as adverse effects of intrathecal metrizamide instillation was prospectively investigated in thirty-three clinical cases admitted to the department of neurosurgery, University of Tokyo Hospital, and Kantoh Teishin Hospital."( [Usefulness and adverse effects of intrathecal metrizamide instillation (author's transl)].
Masuzawa, H; Sano, K; Shimizu, H, 1979
)
0.76
"The adverse effects following lumbar myelography and ventriculography with meglumine iothalamate (Conray Meglumin), meglumine iocarmate (Dimer-X, Bis-Conray) and metrizamide (Amipaque), and after thoracic and cervical myelography and cisternography with metrizamide are reviewed."( Adverse effects of water-soluble contrast media in myelography, cisternography and ventriculography. A review with special reference to metrizamide.
Skalpe, IO, 1977
)
0.66
"The adverse side effects in a series of 439 myelographies with metrizamide were analyzed."( Adverse side effects of metrizamide in myelography.
Gelmers, HJ, 1979
)
0.81
"Selective left vertebral angiography was carried out in 21 rabbits comparing the toxic effects of meglumine iothalamate (Conray meglumine), meglumine metrizoate (Isopaque Cerebral) and metrizamide (Amipaque)."( The toxicity of the non-ionic watersoluble contrast medium metrizamide (Amipaque) in selective vertebral angiography. An experimental study in rabbits.
Skalpe, IO, 1977
)
0.69
"The adverse effects in a series of 50 lumbar myelographies with Amipaque were compared with those in a corresponding series, examined with Dimer-X."( Adverse effects of lumbar myelography with amipaque and dimer-X.
Irstam, L; Selldén, U, 1976
)
0.26
" Mechanisms of severe adverse reactions are reviewed, including the views of Lasser and Lalli, and the view that emphasizes the importance of cardiotoxic and hemodynamic effects."( Chemotoxicity of contrast media and clinical adverse effects: a review.
Dawson, P,
)
0.13
"When cervical myelography is required, the highest incidence of adverse effects usually supervenes."( Low dose cervical CT myelography. How acceptable are adverse effects at this juncture?
Ahn, HS; Kim, WS; Kumar, AJ; Rosenbaum, AE; Updike, ML; Wang, H; Zinreich, SJ, 1986
)
0.27
" Conversely, among 73 patients from whom 20-25 ml of cerebrospinal fluid with the contrast medium was removed, only 10 (14%) experienced adverse effects, a statistically significant reduction."( Myelography with metrizamide: effect of contrast removal on side effects.
Keating, J; Mather, FJ; Mizushima, A; Numaguchi, Y; Rege, AB; Rice, JC; Weems, AM,
)
0.47
" sex, excess intracranial flow of metrizamide and myelographic blockage were not shown to have a significant influence on the adverse reactions."( Influence of certain factors on the manifestations of the adverse effects of metrizamide myelography.
du Boulay, GH; Paul, E; Yu, YL, 1986
)
0.78
"Selective vertebral angiography was performed in 28 rabbits in order to compare the adverse effects of two monomeric (metrizamide, iohexol) and two dimeric (iodecol, 2-5410-3) non-ionic water-soluble contrast media."( The toxicity of non-ionic water-soluble contrast media in selective vertebral angiography. An experimental study in rabbits with special reference to the difference between monomeric and dimeric compounds.
Aulie, A; Skalpe, IO, 1985
)
0.48
" Under adverse conditions, high doses and high concentrations of iohexol produced little arachnoiditis, while metrizamide produced mild to moderate arachnoiditis."( Intrathecal toxicity of iohexol vs. metrizamide. Survey and current state.
Haughton, VM,
)
0.62
" Adverse effects of contrast media on kidney function include diuresis, changes in renal blood flow, osmotic nephroses, albuminuria, enzymuria and, most important, glomerular filtration rate."( Contrast media-induced nephrotoxicity. Survey and present state.
Almén, T; Golman, K,
)
0.13
" Adverse effects with arteriography include seizures, transient cortical blindness, brain edema, and spinal cord injury."( Neurotoxicity of radiological contrast agents.
Junck, L; Marshall, WH, 1983
)
0.27
"In a prospective double-blind randomized study involving 40 patients undergoing lumbar myelography, an attempt was made to correlate adverse effects of the examination with contrast medium dosage."( Relationship between contrast medium dose and adverse effects in lumbar myelography.
Lindeboom, SF; vd Burg, W; Vencken, LM; Wilmink, JT, 1984
)
0.27
"Water-soluble contrast agents (metrizamide) provide a finer myelographic assessment of the spinal neuroanatomical structures but at the expense of some occasional toxic side effects."( Double blind study of the toxicity of intrathecal iopamidol and metrizamide in lumbar myelography.
Fox, AJ; Vézina, JL, 1984
)
0.79
" It is concluded that as long as care is taken to avoid the occurrence of excessive contrast in the intracranial subarachnoid space, PMCT is a safe procedure."( Is there an increased risk of early side effects of metrizamide in post-myelogram computed tomography?
du Boulay, GH; Yu, YL, 1984
)
0.52
"Selective vertebral angiography was performed in 29 rabbits in order to compare the adverse effects of three monomeric (iopamidol, iopromide, metrizamide) and one dimeric (iodecol) non-ionic water-soluble contrast medium."( The toxicity of non-ionic water-soluble monomeric and dimeric contrast media in selective vertebral angiography. An experimental study in rabbits.
Skalpe, IO, 1983
)
0.47
" The hyperosmolar, ionic contrast medium, meglumine metrizoate, was far more toxic to the endothelium than the nonionic media, metrizamide and iohexol, which are far less hyperosmolar."( Human endothelial cell culture as an evaluation system for the toxicity of intravascular contrast media.
Börsum, T; Laerum, F; Reisvaag, A,
)
0.34
" The adverse reactions of Amipaque were observed in 29 cases (85%) out of 34 cases initially 1 hour after cervical myelography and disappeared completely in an average of 16 hours."( [Side effects of metrizamide (Amipaque) cervical myelography (author's transl)].
Komatsu, T; Nishimatsu, T; Okada, K; Wada, H, 1982
)
0.6
"In several series of experiments with intracardiac application in anaesthetized dogs, the following contrast media were tested for their adverse effects on excitation and conduction of electrical activity in the heart."( Contrast media-induced side effects on excitation and conduction of electrical activity in the heart on intracardiac application. Investigations in anaesthetized dogs.
Diletti, E; Felix, R; Hahn, N; Logemann, N; Mählmann, J; Pantenburg, R; Potthoff, E; Raqué, B; Schmidt, I; Schuppert, J; Siering, T; Steinijans, V; Stiemert, D, 1981
)
0.26
"Selective left vertebral angiography was carried out in 25 rabbits comparing the toxic effects of iohexol and metrizamide (Amipaque)."( The toxicity of the non-ionic water-soluble contrast media iohexol and metrizamide (Amipaque) in selective vertebral angiography. An experimental study in rabbits.
Skalpe, IO, 1981
)
0.71
" Following metrizamide myelography, patients can be encouraged to be ambulatory without any increase in the incidence of adverse effects."( Incidence of adverse effects following metrizamide myelography in nonambulatory and ambulatory patients.
Clark, P; Sykes, RH; Wasenaar, W, 1981
)
0.92

Pharmacokinetics

ExcerptReferenceRelevance
" Some computed tomographic (CT) implications of these pharmacokinetic studies are discussed."( Pharmacokinetics of contrast media: experimental results in dog and man with CT implications.
Berger, N; Gardeur, D; Lautrou, J; Metzger, J; Millard, JC, 1980
)
0.26

Compound-Compound Interactions

ExcerptReferenceRelevance
"A case of hydromyelia (syringomyelia) combined with hydrocephalus is presented."( [Hydromyelia combined with hydrocephalus].
Fujita, K; Kawaguchi, T; Kim, S; Matsumoto, S; Tamaki, N, 1986
)
0.27
"A neuroradiological technique for demonstrating the empty sella syndrome using a low dose of intrathecally injected Amipaque (metrizamide) combined with computerized tomography scanning is described."( Diagnosis of empty sella syndrome using Amipaque cisternography combined with computerized tomography.
Hoffman, JC; Tindall, GT, 1980
)
0.47

Bioavailability

ExcerptReferenceRelevance
"The appearances of intraperitoneally injected Amipaque and the absorption rate are described."( Absorption of intraperitoneally injected amipaque in the rabbit.
Cohen, MD; Rust, RJ, 1982
)
0.26
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Metrizamide for myelography is dispensed in two dosage aliquots, 3. It would be wiser to restrict the dosage of metrizamide in cisternographic study, expecially in cases of normal CSF circulation.

ExcerptRelevanceReference
" Special interest is paid to site of puncture, positioning of the patients and concentration and dosage of the medium."( Myelography with metrizamide in infants and children.
Bergström, K; Hindmarsh, T; Hugosson, C, 1977
)
0.6
" In the case of iopentol, a dose-response study was performed, 1 ml x 3 and 4 ml x 3 being also tested."( The influence of non-ionic contrast media on the endothelium of small arteries. A comparison of metrizamide, iohexol and iopentol.
Stjernquist, U; Wieslander, JB, 1987
)
0.49
" The first is the failure of current clinical guidelines to adjust the recommended dosage of metrizamide to reflect differences among age groups in brain weight rather than body weight."( Concentration of intrathecal 3H-labeled metrizamide in normal dog brain: age-related differences.
Anderson, GM; Bigelow, RH; Dubravsky, N; Hayman, LA; Pagani, JJ,
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino sugarAny sugar having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency6.30960.044717.8581100.0000AID485294
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency9.20000.005210.865235.4813AID686970
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.04520.000323.4451159.6830AID743066
importin subunit beta-1 isoform 1Homo sapiens (human)Potency18.35645.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency18.35645.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency18.35645.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency22.38720.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1882576Competitive inhibition of yeast hexokinase2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-d-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1882577Competitive inhibition of rat brain hexokinase2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-d-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,448)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901369 (94.54)18.7374
1990's58 (4.01)18.2507
2000's12 (0.83)29.6817
2010's6 (0.41)24.3611
2020's3 (0.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.28 (24.57)
Research Supply Index7.51 (2.92)
Research Growth Index4.01 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials105 (6.13%)5.53%
Reviews49 (2.86%)6.00%
Case Studies384 (22.43%)4.05%
Observational0 (0.00%)0.25%
Other1,174 (68.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]